✨ Free AI Report
Accelerate Diagnostics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Accelerate Diagnostics, Inc.
Company Research

Accelerate Diagnostics, Inc.: Business Overview, Financials & Competitive Analysis

Accelerate Diagnostics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Niche diagnostic player with meaningful clinical impact but struggling with market adoption and profitability. The company operates in a high-value diagnostic niche with proven clinical utility, but faces significant commercialization challenges evidenced by minimal revenue (~$11.7M TTM) relative to its market cap. Stock price volatility and small employee base.

What is Accelerate Diagnostics, Inc.'s industry? Accelerate Diagnostics, Inc. (acceleratediagnostics.com) operates in In-Vitro Diagnostics. AskCyborg classifies Accelerate Diagnostics, Inc. under In-Vitro Diagnostics in its company registry.

Accelerate Diagnostics is an in vitro diagnostics company that provides solutions for the rapid diagnosis of serious infections through developing and commercializing innovative instrumentation for the identification ...

4/ 10Mixed

Cyborg Score thesis

Niche diagnostic player with meaningful clinical impact but struggling with market adoption and...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Accelerate Diagnostics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Accelerate Diagnostics, Inc.

AskCyborg analysts argue the bull and bear cases for Accelerate Diagnostics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Accelerate Diagnostics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Accelerate Diagnostics, Inc. Overview

Pro stress-test →

Accelerate Diagnostics is an in vitro diagnostics company that provides solutions for the rapid diagnosis of serious infections through developing and commercializing innovative instrumentation for the identification and antibiotic susceptibility testing of infectious pathogens. The company's flagship platforms address critical clinical needs in sepsis management and antibiotic stewardship.

Strategic Profile

Pro stress-test →

The company sells products directly and through third-party distributors to hospital microbiology laboratories domestically and internationally. Clinical data demonstrates significant clinical outcomes, including a statistically significant reduction in 30-day mortality for patients receiving faster diagnostic results.

Competitive Landscape

Pro stress-test →

Accelerate Diagnostics competes in the rapid microbial diagnostics space against established clinical laboratory platforms. Main competitors include companies offering traditional blood culture systems and newer molecular diagnostics platforms. The company's differentiation lies in its speed of pathogen identification and antibiotic susceptibility testing, critical for sepsis management.

Industry Context

Accelerate Diagnostics, Inc. operates in In-Vitro Diagnostics.

Key facts

Founded: 1982 · Headquarters: Tucson, US · Employees: 107 · Revenue: $11.69M TTM (January 2026) · Market cap: $860K

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Accelerate Diagnostics, Inc..

  • Clinical evidence shows 6.0% mortality with Accelerate Pheno vs. 15.9% with standard care for bloodstream infections, demonstrating compelling clinical value
  • Revenue of $11.69M TTM (as of January 2026) remains substantially below market expectations for a diagnostic platform company
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Financial data updated through Q1 2026 showing TTM revenue of $11.69M
  • March 2026Scheduled earnings release on March 26, 2026
  • +1 moreTrack every material event for Accelerate Diagnostics, Inc. as it happens. Explore monitoring →
Get alerted when Accelerate Diagnostics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

MALDI BiotyperMass spectrometry-based microbial identification→BD PhoenixAutomated microbiology identification and susceptibility testing→Vitek 2Automated microbial identification and antimicrobial susceptibility testing→

Compare Accelerate Diagnostics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Accelerate Diagnostics, Inc. operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about Accelerate Diagnostics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Accelerate Diagnostics, Inc. and its top competitor on Cyborg Score”
“What did Accelerate Diagnostics, Inc. do this quarter?”
“Is Accelerate Diagnostics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Accelerate Diagnostics, Inc. do?+
Accelerate Diagnostics is an in vitro diagnostics company that provides solutions for the rapid diagnosis of serious infections through developing and commercializing innovative instrumentation for the identification ...
What is Accelerate Diagnostics, Inc.'s Cyborg Score?+
Accelerate Diagnostics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Accelerate Diagnostics, Inc.'s main competitors?+
Named competitors include MALDI Biotyper, BD Phoenix, Vitek 2. The full competitive landscape is in the AskCyborg report.
How can I get the full Accelerate Diagnostics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Accelerate Diagnostics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Accelerate Diagnostics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA